Formulation Development
Pivotal to Provide Specialized Clinical Research Services for New Clinical Trial With Patients That Have COVID-19
Pivotal recently announced it has been contracted to provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma, obtained from…
Histogen Announces Investigational Device Exemption Application
Histogen Inc. recently announced it has submitted an Investigational Device Exemption (IDE) application with the US FDA for the initiation of a….
Mogrify & Sangamo Announce Collaboration & Exclusive License Agreement
Mogrify Ltd and Sangamo Therapeutics recently announced they have executed a collaboration and exclusive license agreement for Sangamo to develop….
Mustang Bio Receives Advanced Therapy Medicinal Product Classification
Mustang Bio, Inc. recently announced that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to….
Esperion Announces Development & Commercialization Agreement With Otsuka Pharmaceutical
Esperion recently announced it has entered into a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of….
Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics
Q BioMed Inc. recently announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and….
Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)
Catalyst Biosciences, Inc. recently announced completion of dosing and the 30-day follow-up period for its Phase 2b trial of SQ dalcinonacog alfa (DalcA). “We are…
INmune Bio Announces Initiation of Clinical Program to Determine if Company’s Platform May Prevent Complications of Cytokine Storm Caused by COVID-19
INmune Bio, Inc. recently announced the initiation of a therapeutic program to treat patients with pulmonary complications from COVID-19 infection with its dominant-negative TNF inhibitor…
Vaxart Announces Positive Preclinical Data for its Oral COVID-19 Vaccine Program
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, recently announced it has obtained positive…
Ascendia Joins the Fight Against COVID-19; Developing Formulations
Ascendia Pharmaceuticals, a specialty CDMO company engaged in the design, formulation, optimization, and manufacture of poorly soluble molecules for various dosage forms with patent-protected technology…
Arcutis Announces Enrollment of First Patient in Phase 1/2b Study
Arcutis Biotherapeutics, Inc. recently announced it has enrolled the first patient in Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule…
COVID-19: Gattefossé Takes Measures & Continues to be Operational
Gattefossé - provider of personal care ingredients and pharmaceutical excipients - is committed to ensuring the protection of its employees and to manufacturing and delivering,…
New COVID-19 Clinical Trial Supported by Octapharma USA
Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, MD, of Sharp Memorial Hospital in San Diego, CA, focused on treating the most critical patients at the….
TFF Pharmaceuticals Announces R&D Collaboration for a Universal Influenza Vaccine
TFF Pharmaceuticals, Inc. recently announced that it has entered into a research collaboration with the University of Georgia’s Center for Vaccines and Immunology (CVI), along with….
HALIX Enters Collaboration for GMP Manufacturing of a COVID-19 Vaccine
HALIX B.V. has recently joined a consortium of partners under the guidance of the University of Oxford, to provide GMP manufacturing services supporting the large scale production of….
Samsung Bioepis Announces US Launch of Oncology Biosimilar for Early & Metastatic HER2-Overexpressing Breast Cancer & Metastatic Gastric Cancer
Samsung Bioepis Co., Ltd. recently announced today that ONTRUZANT (trastuzumab-dttb), a biosimilar of the reference biologic medicine HERCEPTIN (trastuzumab) for the treatment of….
Hovione's Inhaler for High-Dose Delivery Earns Product Design Award
Hovione Technology recently announced its innovative 8Shot Dry Powder Inhaler (DPI) enabling high-dose drug delivery to the lungs has received the Red Dot 2020 Product…
Guardion Health Sciences Announces Launch of Immuno-Supportive/Anti-Oxidant Complex
Guardion Health Sciences, Inc. recently announced that its immuno-supportive/anti-oxidant complex, labeled acuMMUNE , is now commercially available. acuMMUNE is a unique nutraceutical formulation designed with…
Celsion Reports Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase 3 OPTIMA Study
Celsion Corporation recently announced the prescribed minimum number of events of 158 patient deaths has been reached for the second pre-specified interim analysis of the…
7 Hills Pharma Announces COVID-19 Vaccine Program Targeting At-Risk Elderly
7 Hills Pharma, a clinical stage immunotherapy company focused on development of drugs for the treatment and prevention of cancer and infectious diseases, recently announced…